Literature DB >> 22806538

Impaired expression of CD26 compromises T-cell recruitment in human visceral leishmaniasis.

Ambak K Rai1, Chandreshwar P Thakur, Prabin Kumar, Dipendra K Mitra.   

Abstract

An inefficient Th1 response, coupled with skewed Th2 cytokine production, has been implicated to increase susceptibility to visceral leishmaniasis (VL) infection. The expression of the dipeptidyl peptidase Cd26 by polarized Th1 activates a chemokine cascade that recruits Th1 recruitment to the pathologic site. Here, we studied 42 patients with confirmed VL (mean age 24.80 ± 16.26 years; range 3-70 years; 25 males and 17 females), 30 endemic controls, and 10 nonendemic controls. We observed a decrease in constitutive and antigen-induced expression of CD26 on the T cells of VL patients. Soluble CD26 (sCD26) levels in serum and BM were also found to be significantly lower in VL patients. Following successful therapy, increased sCD26 expression was observed. Tuberculosis pleural effusion derived CCR5(+) CXCR3(+) effector T cells showed enhanced chemokine-driven migration in the presence of posttreatment BM aspirate containing high levels of sCD26. Moreover, T-cell migration could be inhibited by blocking RANTES, IP-10, and CD26 signaling from the posttreatment aspirate with Ab. Our results indicate that, in VL patients, impaired expression and secretion of CD26 compromises chemokine activation and thus T-cell recruitment, eventually resulting in a deficient state of local immunity at pathologic sites.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806538     DOI: 10.1002/eji.201141912

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 2.  Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.

Authors:  M Mandapathil
Journal:  HNO       Date:  2016-05       Impact factor: 1.284

Review 3.  Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.

Authors:  Ashwani Sharma; Tarun Virmani; Anjali Sharma; Vaishnavi Chhabra; Girish Kumar; Kamla Pathak; Abdulsalam Alhalmi
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-16       Impact factor: 3.249

Review 4.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

5.  Disparate host immunity to Mycobacterium avium subsp. paratuberculosis antigens in calves inoculated with M. avium subsp. paratuberculosis, M. avium subsp. avium, M. kansasii, and M. bovis.

Authors:  J R Stabel; W R Waters; J P Bannantine; M V Palmer
Journal:  Clin Vaccine Immunol       Date:  2013-04-03

6.  Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis.

Authors:  Shibabrata Mukherjee; Debanjan Mukhopadhyay; Susmita Ghosh; Joyashree N Barbhuiya; Nilay K Das; Mitali Chatterjee
Journal:  J Clin Immunol       Date:  2015-12-07       Impact factor: 8.317

Review 7.  Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids.

Authors:  Anne Geiger; Géraldine Bossard; Denis Sereno; Joana Pissarra; Jean-Loup Lemesre; Philippe Vincendeau; Philippe Holzmuller
Journal:  Front Immunol       Date:  2016-05-31       Impact factor: 7.561

8.  Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis.

Authors:  Prabin Kumar; Pragya Misra; Narendra Kumar Yadav; Sumit Joshi; Amogh A Sahasrabuddhe; Anuradha Dube; Narayan Rishi; Dipendra Kumar Mitra
Journal:  Trop Parasitol       Date:  2019-05-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.